Novel Index Based on Inflammatory Markers Correlates with Treatment Efficacy of Nivolumab for Recurrent/Metastatic Head and Neck Cancer
According to the findings of the present study, systemic inflammatory markers may help predict the prognosis, activation, and exhaustion of circulating T cells. In patients with R/M head and neck cancer treated with nivolumab, systemic inflammatory markers could provide new insights into rational strategies in cancer immunotherapy for R/M head and neck cancer.
Authors
- Hideyuki Takahashi (ORCID: https://orcid.org/0000-0002-2465-3992)
- Hiroe Tada
- Reika Kawabata‐Iwakawa (ORCID: https://orcid.org/0000-0002-3504-1393)
- Kazuaki Chikamatsu (ORCID: https://orcid.org/0000-0002-7739-0102)
Institutions
- Gunma University (JP)
Publication Details
- Journal
- Oncology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1159/000542683
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85